Irish stent startup nets $17M in financing round

Justine Varieur Cadet | | Health Exec | Digital Transformation
Cappella has completed a $17.3 million series C investment, led by new investors, Fountain Healthcare Partners and Mitsui Venture Partners. Enterprise Ireland also participated in the round alongside Cappella's existing investors, Polytechnos Partners and ACT Venture Capital.

Proceeds will be used to finance the launch of Cappella's Sideguard sidebranch stent for the treatment of bifurcated vascular disease in Europe and to advance research and development programs in Galway, Ireland, on additional applications of Cappella's technology in complex coronary artery disease (CAD), according to the company.

"The funding will allow us to expand our pipeline, to supplement ongoing clinical studies and to successfully launch our first product, the Sideguard sidebranch stent," said Art Rosenthal, MD, Cappella's recently appointed CEO. Rosenthal previously served as chairman and CEO of Labcoat and as chief scientific officer of Boston Scientific.

Cappella was founded in 2004 by Antonio Columbo, MD, chief of invasive cardiology at San Raffaele Hospital in Milan, Italy, and Ascher Shmulewitz, MD, PhD, a cardiologist, medical device entrepreneur, with the backing of Polytechnos Venture Partners and ACT Venture Capital.

Justine Varieur Cadet

Related Content

5 ways AI can help make healthcare more affordable for everyone
HIMSS survey report: Beware insider threats to cybersecurity involving AI
Primary care is primed for AI. But is AI aligned with primary care?
Machine learning vs. bodily pain: 5 points of promise and challenge
Generative AI isn’t changing everything for patients and providers—but it’s not leaving much unaffected, either
Antibiotics prescriptions: There’s a large-language model for that

Around the web

Cardiovascular Business
Boston Scientific enters renal denervation market with acquisition worth up to $540M

Boston Scientific has announced another significant M&A deal, scooping up an Israeli medtech company focused on RDN technology. 

Radiology Business
Shift toward imaging outside the hospital could save billions

Harvard’s David A. Rosman, MD, MBA, explains how moving imaging outside of hospitals could save billions of dollars for U.S. healthcare.

Cardiovascular Business
FDA announces catheter recall for Johnson & Johnson PFA system due to stroke risk

The recall comes after approximately 3% of patients treated with the device during the early stages of its U.S. rollout experienced a stroke or transient ischemic attack following surgery. The expected stroke rate is closer to 1%, the FDA explained.